Welcoming Dr. Joseph Hulihan to Cassava Sciences
Cassava Sciences, Inc. has recently appointed Dr. Joseph Hulihan as its new Chief Medical Officer. His significant expertise in clinical development comes at a crucial time for the company, which is dedicated to creating innovative treatments for central nervous system disorders.
Dr. Hulihan's Background and Experience
Dr. Hulihan, who holds a Doctor of Medicine (MD) and a Master of Science in Health Policy, brings more than 25 years of extensive experience in the biotechnology industry. He has a strong track record in developing treatments for epilepsy and other neurological conditions. Before joining Cassava, Dr. Hulihan served as the Chief Medical Officer at Marinus Pharmaceuticals and held senior roles at Janssen Pharmaceuticals, which is part of Johnson & Johnson.
Focus on Tuberous Sclerosis Complex-Related Epilepsy
With the impending clinical study of simufilam—a medication aimed at treating Tuberous Sclerosis Complex (TSC)-related epilepsy—Dr. Hulihan's role is pivotal. His comprehensive knowledge about the TSC community and drug development strategies puts him in a unique position to guide Cassava in its mission. He will spend about half of his time focusing on the clinical development of simufilam.
Excitement for New Opportunities
Expressing his enthusiasm about the new role, Dr. Hulihan stated, "Advancing innovative neurotherapeutics has been the focus of my career, and I look forward to doing so again here at Cassava with simufilam as a potential first-in-class treatment for TSC-related epilepsy." He is particularly eager about initiating a proof-of-concept study in early 2026.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA) is committed to discovering and developing novel therapeutics for serious CNS disorders, including TSC-related epilepsy. The company focuses on simufilam, a proprietary oral small molecule believed to modulate the activity of the filamin A protein, crucial for neuronal development.
Headquartered in Austin, Texas, Cassava continues to push boundaries, committed to transforming the treatment landscape for CNS disorders. Stay tuned as the company embarks on this promising journey under the guidance of Dr. Hulihan.
For More Information
If you're interested in learning more about Cassava Sciences and its innovative developments, please reach out to the following contacts:
Investors
Sandya von der Weid
Email: svonderweid@lifesciadvisors.com
Company Contact
Eric Schoen, Chief Financial Officer
Phone: (512) 501-2450
Email: ESchoen@CassavaSciences.com
Frequently Asked Questions
What role does Dr. Hulihan have at Cassava Sciences?
Dr. Hulihan serves as the Chief Medical Officer and will guide clinical development for simufilam.
What is simufilam?
Simufilam is Cassava's investigational treatment for Tuberous Sclerosis Complex-related epilepsy.
How long has Dr. Hulihan been in the industry?
Dr. Hulihan has over 25 years of experience in clinical development and biotechnology.
Where is Cassava Sciences based?
Cassava Sciences is headquartered in Austin, Texas.
How can investors contact Cassava Sciences?
Investors can reach out via the provided email addresses for inquiries.
